JP Morgan Chase
SGMO

JP Morgan Chase’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

JP Morgan Chase’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-30,000
Closed -$344K – 6010
2018
Q4 		$344K Buy
+30,000
New +$373K ﹤0.01% 4325

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

JP Morgan Chase's SGMO Position: Q1 2026 in Review

JP Morgan Chase held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 489 shares worth $150. The position accounts for ﹤0.01% of the portfolio, ranked #7278.

JP Morgan Chase first reported a position in SGMO in Q2 2013 and has held it in 42 quarters since. The position peaked at $39.2M in Q2 2021. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • JP Morgan Chase held 489 shares of SANGAMO THERAPEUTICS INC worth $150 as of Q1 2026.
  • JP Morgan Chase left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7278 holding.
  • JP Morgan Chase first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 42 quarters since.
  • JP Morgan Chase's SANGAMO THERAPEUTICS INC position peaked at $39.2M in Q2 2021.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.